港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

573.759

+6.4231.13%

涨家数：21

跌家数：12

平家数：1

市盈率：- -

高：582.169

开：567.296

低：567.296

收：567.335

成交量：4,090.57万

成交额：9.90亿

市值：3,666.28亿

流通市值：3,261.82亿

数据加载中...

总览新闻资讯

国家卫健委：基孔肯雅热和发热伴血小板减少综合征纳入乙类传染病管理

劲方医药－Ｂ(02595)出现大手买入66.16万股，成交价$30.1，涉资1.991千万

阿斯达克财经

微创心通－Ｂ－新(02160)股价上升8.911%，现价港币$3.3

阿斯达克财经

德琪医药-B(06996)获创始人、首席执行官、董事长及其他管理层增持股份

开拓药业-B(09939)股东将股票存入华泰香港存仓市值8384.06万港元

劲方医药-B(02595)：黄美凤获委任为联席公司秘书

劲方医药-B(02595)发布年度业绩净亏损17.95亿元同比扩大164.82%

信达生物(01801)与礼来制药的战略合作已生效澄清非收购交易

直击业绩会 | 德琪医药2025年亏损收窄，管理层称预计今年会陆续达成更多合作

每日经济新闻

长寿制药公司 Enlivex 获 2100 万美元债务融资

华昊中天医药-B(02563.HK)：董事会会议延迟至3月30日

爱科百发三闯港股今年1月刚获批首款药物；ADC药物头对头对比：恒瑞医药挑战德曲妥珠单抗｜掘金创新药

每日经济新闻

两家创新医疗器械企业科创板IPO申请获受理

最高飙升298.5%！17家药企净利大涨

中国抗体-B(03681)授出1157.48万份购股权

复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展

赛克赛斯科创板IPO获受理专注于体内可吸收植介入医疗器械赛道

智通财经网

九州通最新公告：控股子公司取得经颅重复磁刺激仪医疗器械注册证

超21亿美元抢滩TCE，吉利德收购康诺亚NewCo合作公司

21世纪经济报道

信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":573.7586,"timestamp":1774411198828,"preClose":567.33514,"halted":0,"volume":40905666,"delay":0,"changeRate":0.011322,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午间休市","change":6.423462,"latestTime":"03-25 12:00:00","open":567.2958,"high":582.169,"low":567.2958,"amount":990207743,"amplitude":0.026216,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774414800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"pbRate":5.099055,"peRate":-59.113168,"turnoverRate":0.001492,"increases":21,"decrements":12,"flats":0,"marketCap":366627755744,"floatMarketCap":326182401296},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":582.169,"amplitude":0.026216,"preClose":567.33514,"low":567.2958,"pbRate":"5.099055","latestPrice":573.7586,"volume":40905666,"delay":0,"open":567.2958,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":588.613,"twentyDayClose":559.164,"sixtyDayClose":577.927,"secType":"PLATE","market":"HK","turnoverRate":0.001492,"peRate":-59.113168,"marketCap":366627755744,"floatMarketCap":326182401296,"timestamp":1774411198828,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":12,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622043294","title":"国家卫健委：基孔肯雅热和发热伴血小板减少综合征纳入乙类传染病管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043294","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043294?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 10:37","pubTimestamp":1774406270,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国家卫生健康委今天发布公告，根据《中华人民共和国传染病防治法》相关规定，自2026年4月1日起将基孔肯雅热和发热伴血小板减少综合征纳入乙类传染病进行管理，并采取乙类传染病的预防、控制措施。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/Y2Y0ZjIxMzUyMzg0MDEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2Y0ZjIxMzUyMzg0MDEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2045819591.USD","LU1961090484.USD","BK1583","IE00B543WZ88.USD","LU1720050803.USD","LU0348735423.USD","LU0348784397.USD","LU0320764599.SGD","LU0417516571.SGD","BK1576","LU0540923850.HKD","LU2125910500.SGD","BK1574","IE00B5MMRT66.SGD","LU0417516902.SGD","BK1161","LU0052750758.USD","LU0348767384.USD","LU0561508036.HKD","LU2242644610.SGD","LU0348783233.USD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","LU0634319403.HKD","LU0348827113.USD","LU2399975544.HKD","LU2488822045.USD","LU0417516738.SGD","LU2778985437.USD","LU0348766576.USD","LU0708995583.HKD","LU1046422090.SGD","LU2476274308.USD","02359","LU2476274720.SGD","LU0348825331.USD","BK1141"],"gpt_icon":0},{"id":"2622043117","title":"劲方医药－Ｂ(02595)出现大手买入66.16万股，成交价$30.1，涉资1.991千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043117","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043117?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 10:25","pubTimestamp":1774405500,"startTime":"0","endTime":"0","summary":"[大手成交]劲方医药－Ｂ(02595)在上午10:25出现大手买入，成交量为66.16万，成交价为港币$30.1，涉资1.991千万。至目前为止，股价升5.907%，今日最高价为$30.12，而最低价为$27.52，总成交量为220.902万股，总成交金额港币$6.55千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603255375/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603255375/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02595","BK1574","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2622043584","title":"微创心通－Ｂ－新(02160)股价上升8.911%，现价港币$3.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043584","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043584?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 10:05","pubTimestamp":1774404300,"startTime":"0","endTime":"0","summary":"[上升股]微创心通－Ｂ－新(02160) 股价在上午10:05比前收市价上升8.911%，现股价为港币$3.3。至目前为止，今日最高价为$3.3，而最低价为$3.09。总成交量为18.7万股，总成交金额为港币$59.276万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603252429/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603252429/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","02160","BK1574","BK1583"],"gpt_icon":0},{"id":"2622126670","title":"德琪医药-B(06996)获创始人、首席执行官、董事长及其他管理层增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622126670","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622126670?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 08:19","pubTimestamp":1774397993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，本公司董事会获本公司创始人、执行董事、首席执行官兼董事长梅建明博士告知，于2026年3月23日及24日，梅博士透过其控制的一间实体于公开市场以平均价格每股约0.512美元购入本公司合共20万股普通股，占已发行股份总数约0.029%。在遵守适用法律及监管规定的前提下，彼等不排除于适当时候进一步增持本公司股份的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK1583","06996"],"gpt_icon":0},{"id":"2622142540","title":"开拓药业-B(09939)股东将股票存入华泰香港 存仓市值8384.06万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622142540","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622142540?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 08:06","pubTimestamp":1774397197,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月24日，开拓药业-B(09939)股东将股票存入华泰香港，存仓市值8384.06万港元，占比6.11%。开拓药业-B公告，其自主研发、潜在同类首创的 KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已获得顶线数据。数据显示，该III期阶段达到主要研究终点，结果具有统计学显著性及临床意义，且有效性和安全性均表现出色。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2622014592","title":"劲方医药-B(02595)：黄美凤获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014592","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622014592?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 07:52","pubTimestamp":1774396324,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，吴东澄因其专业事务重新安排及更深入参与客户业务及策略管理，已提呈辞任联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。黄美凤已获委任为联席公司秘书、授权代表及法律程序文件代理人，自2026年3月24日起生效。张巍将继续担任公司另一名联席公司秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02595","159938","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2622145900","title":"劲方医药-B(02595)发布年度业绩 净亏损17.95亿元 同比扩大164.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622145900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622145900?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 07:50","pubTimestamp":1774396243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布截至2025年12月31日止年度业绩，收入人民币1.3亿元，同比增长24.42%;研发成本2.82亿元，同比减少15.01%;净亏损17.95亿元，同比扩大164.82%。公司历年来达成多个国内外授权交易，营业收入保持稳健。2025年度营业收入超过1.3亿元人民币、同比增幅近25%。此外公司现金流储备充足，截至2025年底现金及银行结余超过20亿元人民币。同时本公司是唯一一家在上市时拥有已商业化的1类创新药并产生对外授权收入的上市规则第18A章上市公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","02595","BK1574","159938","BK1515"],"gpt_icon":0},{"id":"2622001480","title":"信达生物(01801)与礼来制药的战略合作已生效 澄清非收购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001480?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 07:43","pubTimestamp":1774395814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域新药研发所作出的公告。公司已获联邦贸易委员会提前批准，至此，礼来制药与公司之间战略合作协议生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。公司注意到，部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清，公司并未，亦无意进行该等交易。谨此提醒股东及有意投资者，切勿依赖有关集团的市场传闻。有关集团的任何资讯，应仅以公司的官方公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B4JS1V06.HKD","LU2756315664.SGD","IE00BKPKM429.USD","SGXZ31699556.SGD","BK1583","LU0672654240.SGD","LU1093756168.USD","SG9999013999.USD","LU1551013342.USD","LU2360106947.USD","LU0683600562.USD","LU2168564222.USD","LU2896262040.SGD","LLYX","LU2488822045.USD","SG9999014898.SGD","IE0009355771.USD","LU2237443978.SGD","LU1868836914.USD","LU2602419157.SGD","LU0455707207.USD","LU1814569148.SGD","LU0354030511.USD","LU2168564495.EUR","LU0417517546.SGD","IE00B1XK9C88.USD","LU2023250330.USD","LU2471134952.CNY","IE00BWXC8680.SGD","BK4516","BK1574","LU0708995401.HKD","LLII","LU0823416689.USD","LU1291159041.SGD","BK1161","SG9999015945.SGD","LU1868836757.USD","IE0001KFT4U8.USD","LU1127390331.HKD","LU2552382132.HKD","LU0502904849.HKD","LU2552382215.SGD","IE00B7KXQ091.USD","LU0471298777.SGD","LU1548497426.USD","LU0787776722.HKD","LU2087625088.SGD","LU2456880835.USD","IE00B1BXHZ80.USD","LU2491050154.USD","LU2211815571.USD","LU2213496289.HKD","SGXZ51526630.SGD","LU2106854487.HKD","LU0238689110.USD","IE00B2B36J28.USD","SGXZ57979304.SGD","LU0786609619.USD","SG9999014906.USD","LU1989771016.USD","IE00BJJMRY28.SGD","LU0289739699.SGD","LU0471298694.HKD","LU2264538146.SGD","LU0353189680.USD","LU2357305700.SGD","BK4599","ELIS","SG9999015952.SGD","LU0354030438.USD","LU0432979614.USD","LU2097828474.EUR","LU2471134796.USD","LU1280957306.USD","LU0058720904.USD","LU0203202063.USD","LU2089284900.SGD","LU2089984988.USD","GB00BDT5M118.USD","BK4585","SG9999014880.SGD","LU1093756325.SGD","LU0266013472.USD","LU1267930730.SGD","LU1323610961.USD","LU2491050071.SGD","LU1969619763.USD","LU0640476718.USD","LU0320765059.SGD","IE0005OL40V9.USD","LU2471134879.HKD","LU1023059063.AUD","IE00BJT1NW94.SGD","BK4533","LU0256863811.USD","LU0385154629.USD","LU0882574139.USD","LU1061106388.HKD","LU2328871848.SGD","SG9999015986.USD","IE00BJLML261.HKD","LU1804176565.USD","LU0225283273.USD","LU2237438978.USD","LU2237443382.USD","BK4588","LU0964807845.USD","LU1988902786.USD","LU2361044865.SGD","LU2471134523.USD","SG9999001176.SGD","LU2168564065.EUR","LU1232071149.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0889565916.HKD","LU0234572021.USD","LU1366192091.USD","IE00B4R5TH58.HKD","LU0353189763.USD","LU2089283258.USD","LU1145028129.USD","LU2746668974.SGD","SG9999018857.SGD","LU0097036916.USD","LLYZ","LU2237443549.SGD","BK1191","01801","LU2271345857.HKD","LU2168564149.EUR","SGXZ99366536.SGD","LU1917777945.USD","LU0061475181.USD","LU1868837136.USD","LU2097828631.EUR","LU1035775433.USD","IE00BK4W5L77.USD","LU0256863902.USD","LU2417539215.USD","LU0114720955.EUR","LU2552382058.USD","IE00BFSS7M15.SGD","LU0820561909.HKD","BK4534","LU2324357040.USD","ELIL","LU2168563687.JPY","LU0122379950.USD","LU1868836591.USD","LU2468319806.SGD","IE00BK4W5M84.HKD","LU2097828557.USD","LU1069344957.HKD","LU2461242641.AUD","LU2097828714.EUR","LU0106261372.USD","LU2111349929.HKD","LU0109391861.USD","IE00BFSS8Q28.SGD","LU1623119135.USD","LU0320765992.SGD","LU2265009873.SGD","SG9999001176.USD","LU0158827948.USD","LU2023250504.SGD","LU0203201768.USD","LU1057294990.SGD","LU2746668461.USD","LU0689472784.USD","IE0004445015.USD","IE0004445239.USD","LU2491049909.HKD","LU0210536198.USD","LU2756315318.SGD","BK4581","BK1589","LU2108987350.USD","LU2237443895.HKD","SG9999014914.USD","LU1064131342.USD","LU1868837300.USD","LU1983299246.USD","LU2237443465.HKD","IE00BKDWB100.SGD","LU0109394709.USD","IE0002141913.USD","SG9999017495.SGD","LU2462157665.USD","IE00B775H168.HKD","LU0456855351.SGD","LU2236285917.USD","LU1720051017.SGD","LU2361044949.HKD","LU2750360641.GBP","LU2028103732.USD","LU0820562030.AUD","LU1712237335.SGD","LU0316494557.USD","LU1720051108.HKD","LU0158827781.USD","BK4007","LU0823434583.USD","LU2023251221.USD","SG9999018865.SGD","LU1974910355.USD","LU2361045086.USD","LU0323591593.USD","LU2242644610.SGD","LU1551013425.SGD","IE00BJJMRX11.SGD","IE00BFTCPJ56.SGD","LU2097828805.USD","SG9999015978.USD","LU0823434740.USD","LU0882574055.USD","LU2750360997.AUD","LU0006306889.USD","LU1629891620.HKD","LU0094547139.USD","LU0466842654.USD","LU0943347566.SGD","LU0820561818.USD","LU0079474960.USD","LU2063271972.USD","SGXZ81514606.USD","LU0198837287.USD","HK0000165453.HKD","IE00BN29S564.USD","LU2237443622.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2622509942","title":"直击业绩会 | 德琪医药2025年亏损收窄，管理层称预计今年会陆续达成更多合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622509942","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622509942?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 23:49","pubTimestamp":1774367382,"startTime":"0","endTime":"0","summary":"3月20日，德琪医药（6996.HK）发布2025年年度业绩公告，并于3月23日召开业绩说明会，披露了全年经营数据及核心管线、技术平台的最新进展。财务数据显示，德琪医药2025年实现营业收入1.05亿元，同比增长14.56%，经调整后年内亏损（扣除汇兑差异净额）为2.02亿元，上年同期亏损为3.04亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682959074.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682959074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1574","BK1583","06996"],"gpt_icon":0},{"id":"2621964280","title":"长寿制药公司 Enlivex 获 2100 万美元债务融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2621964280","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621964280?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 22:57","pubTimestamp":1774364278,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据市场消息，长寿医药及 RAIN 代币资产库 Enlivex 宣布获得纽约机构基金 The Lind Partners 提供的 2100 万美元债务融资。公司称将继续执行其预测市场代币资产库策略，新增约 30 亿枚 RAIN 代币，并用于支持公司运营计划。Enlivex 为纳斯达克上市公司，正在开发治疗骨关节炎等关节疾病的疗法，同时作为 RAIN 数字资产库持有大规模 RAIN 头寸。RAIN 为部署在 Arbitrum 网络上的去中心化预测市场协议代币，其协议通过 AI 判定结果并采用回购销毁机制。Enlivex 股价当前约为 1.05 美元，日内下跌约 5%。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2254180","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2621932850","title":"华昊中天医药-B(02563.HK)：董事会会议延迟至3月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=2621932850","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621932850?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 22:17","pubTimestamp":1774361827,"startTime":"0","endTime":"0","summary":"格隆汇3月24日丨华昊中天医药-B(02563.HK)宣布，由于公司及其核数师需要额外时间审阅及落实年度业绩，董事会会议日期将由2026年3月25日(星期三)延迟至2026年3月30日(星期一)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260324/32094959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","09939","BK1574","BK1515","BK1161","02563"],"gpt_icon":0},{"id":"2621093082","title":"爱科百发三闯港股 今年1月刚获批首款药物；ADC药物头对头对比：恒瑞医药挑战德曲妥珠单抗｜掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093082","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621093082?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 22:16","pubTimestamp":1774361773,"startTime":"0","endTime":"0","summary":"一周行情上周（3月16日至3月20日）医药生物指数下跌1.38%，跑赢上证指数2个百分点。创新药（BK1106）周内下跌3.57%；恒生医疗保健业指数（HSCICH）周内下跌0.33%；港股创新药ETF（513120）周内下跌0.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682906186.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682906186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245177.USD","BK0028","LU2097828474.EUR","600276","LU2097828557.USD","LU2328871848.SGD","BK4231","LU1064130708.USD","LU1146622755.USD","BK0188","LU2580892789.USD","LU2495084118.USD","LU0359201612.USD","LU1580142542.USD","LU1997245094.SGD","LU1820825898.SGD","BK0012","LU2289578879.USD","BK4588","LU1969619763.USD","LU1781817850.SGD","LU0405327494.USD","BK4585","01276","LU2148510915.USD","LU0359201885.HKD","LU2097828805.USD","LU2097828714.EUR","BK0060","BK1574","159992","BK4080","ADC","BK0183","LU2097828631.EUR","VXUS","LU1064131003.USD","LU2488822045.USD","LU1328615791.USD","LU0359202008.SGD","BK1191","LU2543165471.USD","LU1255011170.USD","LU0405327148.USD","BK0239","LU2580892862.HKD","LU1023057109.AUD","LU1655091616.SGD","06978","BK1161"],"gpt_icon":0},{"id":"2621062006","title":"两家创新医疗器械企业科创板IPO申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062006","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062006?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 20:40","pubTimestamp":1774356000,"startTime":"0","endTime":"0","summary":"　　上交所官网显示，今日艾柯医疗器械（北京）股份有限公司和赛克赛斯生物科技股份有限公司科创板IPO申请获受理。目前，科创板已成为中国医疗器械硬科技企业的产业高地，随着一批国产高端医疗器械“链主”企业在科创板上市，带动了产业链协同创新效应，以艾柯医疗、赛克赛斯为代表的专精特新、“小巨人”企业也有望通过资本市场实现中国医疗器械行业由“量变”到“质变”的跨越。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-03-24/doc-inhscaew0392664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1222","BK1574","BK1583","159982","09996","159883","BK1100","09997"],"gpt_icon":0},{"id":"2621062001","title":"最高飙升298.5%！17家药企净利大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062001","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062001?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 20:13","pubTimestamp":1774354380,"startTime":"0","endTime":"0","summary":"中药板块中，传统中药龙头如白云山、华润三九归母净利润增速较为平缓，分别为5.21%、1.58%，中小中药企业如特一药业、沃华医药增速极高，分别为298.5%、162.93%。高增长背后，医药工业是特一药业核心收入来源，2025年占总营收98.22%，同比增长35.21%；板块毛利率54.94%，同比提升10.77%，核心产品包括止咳宝片、血塞通分散片等。CXO赛道的药明康德在2025年业绩再创新高，营收达到454.56亿元，同比增长15.84%；归属于上市公司股东净利润191.51亿元，同比增长102.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-24/doc-inhscaeu4141644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2621061761","title":"中国抗体-B(03681)授出1157.48万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061761?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 19:54","pubTimestamp":1774353294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，于2026年3月24日，公司已根据2022年购股权计划向2名合资格人士授出1157.48万份购股权。购股权赋予承授人权利认购合共1157.48万股公司新股份，但须待承授人接纳后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"gpt_icon":0},{"id":"2621069488","title":"复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069488?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0060","BK0183","06978","BK0196","BK0096","BK1574","BK0187","BK0028","BK1191","BK0188","BK1161","600196","159992","BK0175","BK1593","BK0239","BK0012","BK1515"],"gpt_icon":0},{"id":"2621066933","title":"赛克赛斯科创板IPO获受理 专注于体内可吸收植介入医疗器械赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066933","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066933?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 18:48","pubTimestamp":1774349332,"startTime":"0","endTime":"0","summary":"3月24日，赛克赛斯生物科技股份有限公司上交所科创板IPO已受理，拟募资6.35亿元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260324/20260324184134_36345.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260324/20260324184134_36345.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159982","BK1222","BK1100","159883","09997","BK1583","09996","BK1574"],"gpt_icon":0},{"id":"2621063298","title":"九州通最新公告：控股子公司取得经颅重复磁刺激仪医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063298","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063298?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 17:57","pubTimestamp":1774346230,"startTime":"0","endTime":"0","summary":"九州通(600998.SH)公告称，公司控股子公司武汉柯尼兹医疗科技有限公司近日获得湖北省药监局核准签发的“经颅重复磁刺激仪”医疗器械注册证(编号：鄂械注准20262096046)，有效期至2031年3月17日，适用于3岁以上儿童及成人缺血性脑血管病、脑损伤性疾病的辅助治疗。该产品注册证的取得有助于丰富公司医疗器械产品线，推动“新产品”战略落地，但实际销售受行业政策、市场需求等因素影响，未来业绩贡献存在不确定性。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260324/32094329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0201","BK0196","BK0188","BK1583","BK0039","09997","BK0250","BK1100","BK0146","BK1222","09996","159883","600998","BK0028","BK0077","BK0012","BK0187","BK1574","BK0097"],"gpt_icon":0},{"id":"2621068652","title":"超21亿美元抢滩TCE，吉利德收购康诺亚NewCo合作公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068652","media":"21世纪经济报道","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068652?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 17:20","pubTimestamp":1774344000,"startTime":"0","endTime":"0","summary":"3月24日，康诺亚（02162.HK）发布公告称，公司NewCo合作企业OuroMedicines已与吉利德科学（简称“吉利德”，NASDQ：GILD）签署并购协议，吉利德将以并购方式收购OuroMedicines。此次交易总金额可达21.75亿美元，包括16.75亿美元首付款（可按惯例调整）和最高5亿美元里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682648353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682648353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1587","BK1574","02162","BK1161"],"gpt_icon":0},{"id":"2621057186","title":"信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621057186?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 16:45","pubTimestamp":1774341908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0145注射液(项目代码：SAL0145)开展MASH适应症的临床试验。SAL0145是公司研发的具有自主知识产权的siRNA药物。临床前研究显示，其具有治疗MASH的潜力。若能研发成功并获批上市，将有望为更多患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1574","BK0239","BK0183","BK0187","BK0028","BK0196","BK1161","002294","BK0188","06978"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":1,"totalSize":313,"code":"91000000","status":"200"}]}}